Chat with us, powered by LiveChat


Cancer Biopsy Market Report


Cancer Biopsy Market by Product (Instruments, Kits & Consumables, and Services), Type (Tissue Biopsies and Liquid Biopsies), Application (Colorectal Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Liver, Pancreatic Cancer, Ovarian Cancer, and Others), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032


Pages: 290

Oct 2023

Cancer Biopsy Overview

A biopsy is a process that involves removing a piece of tissue or a sample of cells from a patient’s body to be analyzed in a laboratory. A biopsy may be performed if the patient is experiencing certain symptoms or if the doctor has discovered an area of concern. A biopsy can tell if the patient has cancer or another illness. The rising cancer incidence across the globe is one of the primary drivers of the cancer biopsy market. According to a WHO report published in 2022, cancer is the largest cause of mortality in the globe, accounting for over 10 million deaths in 2020, or roughly one in every six.

Accurate and fast cancer detection is critical for efficient treatment planning and improved patient outcomes. Cancer biopsies give essential information on cancer cells' existence, type, stage, and molecular properties. They aid in determining the best treatment strategy, which may include targeted treatments, immunotherapies, or surgery. Biopsy method advancements have also contributed to the market's expansion. Traditional biopsy techniques, such as surgical biopsies, are frequently invasive, time-consuming, and risky. However, due to their decreased risk, shorter recovery time, and ability to produce correct diagnostic results, minimally invasive procedures such as needle biopsies have gained favor.

Global Cancer Biopsy Market Analysis

The global cancer biopsy market size was $22,228.50 million in 2022 and is predicted to grow at a CAGR of 11.4%, by generating a revenue of $64,231.97 million by 2032.

COVID-19 Impact on Global Cancer Biopsy Market

The COVID-19 pandemic has had a significant effect on cancer biopsy techniques and subsequent cancer diagnoses. The pandemic's disturbances, such as lockdown measures, healthcare system strain, and patient worries, have resulted in a significant decline in these critical diagnostic procedures. Because of the necessity to prioritize COVID-19 patients and conserve resources, many medical facilities around the world encountered difficulties in performing cancer biopsies. As a result, compared to pre-pandemic levels, the number of colonoscopies, prostate biopsies, chest computed tomography scans, and cystoscopies declined by significant percentages.

In the post-COVID-19 era, the cancer biopsy market has seen considerable changes. While the pandemic originally caused disruptions and decreases in cancer biopsy procedures, the market has shown resilience and adapted to the changing circumstances. Cancer biopsy methods have seen a return as healthcare systems progressively recover from the pandemic's initial impact. Medical facilities have adopted safety standards and techniques to prioritize key diagnostic tests, including biopsies, in order to solve the backlog of missed screens and diagnoses. The market is seeing a resurgence in biopsy volumes but at varied rates across regions.

Increasing Number of Cancer Patients Across the World to Drive the Market Growth

The increasing number of cancer patients globally is a vast driver for the growth of the cancer biopsy market. Cancer remains a main cause of morbidity and mortality globally, and early and correct analysis is critical for its cure. The incidence of cancer continues to rise, due to various factors such as growing older populations, lifestyle changes, environmental factors, and improved recognition and screening efforts. As more people are diagnosed with cancer, there is a growing need for diagnostic systems like biopsies to verify the presence of cancer, determine its type and stage, and guide treatment decisions. Biopsies play a fundamental function in cancer diagnosis, presenting crucial statistics about cancer tumor characteristics and guiding cure strategies. They help determine the histological type of cancer, molecular markers, and genetic alterations, which are essential for personalized cure planning. The growing focus on precision remedies and centered treatment plans further emphasizes the importance of accurate analysis of most cancers through biopsies.

The development of superior biopsy techniques, such as image-guided biopsies, minimally invasive procedures, and liquid biopsies, has expanded the accessibility and effectiveness of cancer diagnosis. These advancements enable earlier detection, decreased patient discomfort, and better sampling of tumors, thus ensuring improved diagnostic accuracy and patient outcomes. Moreover, many international organizations have rolled out  cancer screening packages and awareness initiatives to make people aware of cancer at early stages when it is treatable. These packages emphasize the importance of timely analysis through biopsies, driving the demand for biopsy procedures. Increased public awareness about most cancers’ symptoms and the availability of diagnostic options also contribute to the growth of the cancer biopsy market.

Security Concerns to Restrain the Market Growth

The cancer biopsy market is expected to face some restraints due to certain security concerns. One great concern is the possible compromise of data privacy and security. Cancer biopsy entails the collection and evaluation of patients’ sensitive medical information, inclusive of genetic data, etc. Safeguarding these statistics is crucial to protect patient confidentiality and forestall unauthorized get entry or breaches. Instances of statistical breaches or privacy issues can erode an affected person’s trust and lead to reluctance in undergoing biopsies and negatively impacting market growth. Additionally, the growing reliance on digital systems and connectivity in healthcare introduces cybersecurity risks. Cybercriminals may target medical devices, digital fitness records, or verbal exchange networks associated with cancer biopsies. Successful cyber assaults can disrupt operations, compromise the affected person’s facts integrity, and undermine the confidence of both patients and healthcare providers. The worry of cybersecurity vulnerabilities may also make healthcare institutions and patients hesitant to adopt or utilize biopsy-related technologies, impeding market growth.

Advancements in Technology to Drive Excellent Opportunities

A significant development in the realm of cancer biopsy is liquid biopsy, which presents fantastic market expansion prospects. This non-invasive procedure involves the examination of tumor-derived genetic material detected in a patient's blood or other bodily fluids, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), or exosomes.  Liquid biopsy can identify the existence of cancer-related mutations or alterations in the bloodstream at an early stage when tumors are tiny and difficult to see with conventional imaging or tissue biopsies.

Global Cancer Biopsy Market Share, by Product, 2022

The kits & consumables sub-segment accounted for the highest market share in 2022. Biopsy needles are utilized to collect tissue samples from suspected malignant regions. Core biopsy needles, needles for fine-needle aspiration (FNA), and vacuum-assisted biopsy (VAB) needles are few of the several shapes and sizes available for use in biopsies. Chemicals called reagents and stains are used to process and prepare biopsy samples for analysis. They assist in fixing, staining, and preserving tissue samples so that they can be examined under a microscope and aberrant cells can be identified. For a particular molecular or genetic analysis, assay kits, such as polymerase chain reaction (PCR) kits, fluorescent in situ hybridization (FISH) kits, or immunohistochemistry (IHC) kits, comprise specialized chemicals and materials. Due to such diverse factors, the market for cancer biopsy kits and consumables is anticipated to boost market growth.

Global Cancer Biopsy Market Share, by Type, 2022

The tissue biopsies type sub-segment accounted for the highest market share in 2022. Tissue biopsy is a well-established and extensively used approach for diagnosing and treating a number of kinds of cancer. Tissue biopsies are regarded as the major method preferred for cancer diagnosis, imparting histological and molecular facts about the tumor. They contain the collection of tissue samples immediately from the tumor site, permitting pathologists to observe cell and tissue architecture, perceive peculiar cells, decide the tumor's kind and grade, and verify a range of biomarkers. The high diagnostic accuracy of tissue biopsies makes them indispensable for treatment decision-making and patient management. Tissue biopsies enable precise localization of the tumor within the body and grant data about its size, extent, and involvement of nearby structures. This helps in tumor staging, which is indispensable for determining the suitable treatment method and prognosis.

Global Cancer Biopsy Market Share, By Application

The breast cancer sub-segment accounted for the highest market share in 2022. Breast cancer is a type of cancer that develops in the cells of the breasts. Breast cancer is the second most prevalent cancer diagnosed in women in the United States, after skin cancer. Breast cancer can affect both men and women, but it affects women significantly more frequently. A breast biopsy is a technique that involves the removal of a sample of breast tissue for testing. The tissue sample is submitted to a lab, where pathologists (doctors who specialize in analyzing blood and bodily tissue) evaluate it and provide a diagnosis.

   Global Cancer Biopsy Market Share, by Region, 2022

The North American cancer biopsy market generated the highest revenue in 2022. The market North America region is predicted to increase its share in the future, owing to the improved adoption of different cancer remedies and the developing burden of cancers in the United States. According to the Globo Cancer 2020 report, an estimated 2,281,658 new cancers cases were recognized in the United States in 2020, with almost 612,390 deaths. In 2020, The most prevalent cancers had been breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the United States. Additionally, the increasing awareness of key players in North America, growing FDA approvals strategic alliances, and excessive funding in research and improvement activities are anticipated to increase the market in the region. For instance, in November 2020, Merck & Co. Inc entered into a definitive settlement to acquire Velosbio Inc., which is a privately held clinical-stage biopharmaceutical organization committed to develop technologically advanced cancers healing procedures focused on receptor tyrosine kinase-like orphan receptor 1 (ROR1). Similarly, in March 2020, Johnson and Johnson received the US FDA Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small mobile phone lung cancer (NSCLC). Thus, given the aforementioned factors, the cancer remedy market is anticipated to grow significantly over the forecast length in North America.

Competitive Scenario in the Global Cancer Biopsy Market

Innovations, acquisitions, and product launches are common strategies followed by major market players. For instance, in July 2022, BillionToOne, a next-generation molecular diagnostics firm, announced the launch of its first oncology liquid biopsy tools, Northstar Select and Northstar Response. The products are now available for use in research at a few academic cancer centers.

Some of the distinguished players in the cancer biopsy market include Qiagen N.V., Illumina, Inc., ANGLE Plc, BD (Becton, Dickinson and Company), Myriad Genetics, Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, and F. Hoffmann-La Roche Ltd.



Historical Market Estimations


Base Year for Market Estimation


Forecast Timeline for Market Projection


Geographical Scope

North America, Europe, Asia-Pacific, and LAMEA

Segmentation by Product

  • Instruments
  • Kits and Consumables
  • Services

Segmentation by Type

  • Tissue Biopsies
  • Liquid Biopsies


Segmentation by Application



  • Colorectal Cancer
  • Breast CancerLung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Liver
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others



Key Companies Profiled

  • Qiagen N.V.
  • Illumina, Inc.
  • ANGLE Plc
  • BD (Becton, Dickinson and Company)
  • Myriad Genetics
  • Hologic, Inc.
  • Biocept, Inc.
  • Thermo Fisher Scientific, Inc.
  • Danaher
  • F. Hoffmann-La Roche Ltd.



Frequently Asked Questions

A. The size of the global cancer biopsy market was over $22,228.50 million in 2022 and is projected to reach $64,231.97 million by 2032.

A. Thermos Fisher Scientific Inc. and Abbott Laboratories are some of the key players in the global communication software market.

A. The North America region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. Agreement and investment are the two key strategies opted by the operating companies in this market.

A. Qiagen N.V. Illumina, Inc. ANGLE Plc and BD (Becton, Dickinson and Company) are the companies investing more in R&D activities for developing new products and technologies.

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed